Orchid Pharma opened lower at ₹896.75, compared with its previous close of ₹902.15. In the last trading session on 6 Nov 2026, the stock traded between ₹862.55 and ₹896.75, with an average traded price of ₹871.79. It showed a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Orchid Pharma is now worth
₹ 21,958.00
giving a profit of
₹ 11,958.00 (119.58%)
Note: Past profits do not guarantee future returns.
Rating by Refinitive from 1 Analysts
Today's Change
-34.15 (-3.79%)
Day High
₹896.75
Day Low
₹862.55
Day Open
₹896.75
Prev Close
₹902.15
Volume
31,380
Value Traded
₹2.74 Cr
1W Return
-2.84%
1M Return
-10.14%
3M Return
-12.35%
6M Return
38.36%
1Y Return
9.82%
Market Cap (₹ Cr.)
5,198
PE Ratio
504.30
PB Ratio
3.46
Dividend Yield
-
ROE
0.68%
ROCE
1.10%
Book Value (₹)
261.22
Face Value (₹)
10.00
EPS (TTM)
0.54
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-2.84%
6 Weeks
-
1 Month
-10.14%
3 Months
-12.35%
9 Months
26.58%
Orchid Pharma signs $80m Latin America deal for Exblifep with Libra
Orchid Pharma signs licensing deal with Laboratorio Libra for Exblifep in nine Latin American countries. Partnership targets potential commercial opportunity of approximately $80 million over 10 years. Libra secures exclusive rights to register, import, and market the drug; Orchid supplies finished dosage form. Exblifep is the first Indian-invented new chemical entity approved by both US FDA and European EMA.
16 days agoOrchid Pharma board approves enabling resolution to raise up to ₹600 crore
Orchid Pharma board approves enabling resolution to raise up to ₹600 crore. Funds may be raised via equity, convertible debentures, or warrants. Meeting held on October 20, 2026, subject to shareholder approval.
20 days agoOrchid Pharma adopts revised FY26 financials at 33rd AGM
Orchid Pharma adopted revised standalone and consolidated financial statements for FY26 at its 33rd AGM. Consolidated auditor's report contained qualifications; standalone report remained unqualified. Mridul Dhanuka reappointed as Whole-Time Director; Arjun Dhanuka appointed as new Whole-Time Director. Approval granted for material related party transactions with Otsuka Chemical (India) Private Limited.
1mo agoOrchid Pharma lists 4.45 crore equity shares on NSE and BSE
Orchid Pharma listed 4,45,86,052 equity shares on NSE and BSE from September 23, 2026. Shares were allotted under a scheme of amalgamation approved by the NCLT, Chennai Bench. The company filed intimation under Regulation 30 of SEBI Listing Regulations.
1mo agoOrchid Pharma buys Kancheepuram land, ends DBS Bank lease
Orchid Pharma acquired land in Kancheepuram District, Tamil Nadu. Lease arrangement with DBS Bank India Limited formally concluded. Company secured permanent ownership rights over the property.
1mo agoOrchid Pharma schedules Mumbai investor roadshow for late September
Orchid Pharma schedules an investor roadshow in Mumbai from September 28 to 30, 2026. Whole Time Director Mridul Dhanuka will lead the physical group meets. The company filed the intimation under SEBI LODR Regulation 30. No unpublished price-sensitive information will be shared during the event.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,904.50 | -0.55% | ₹4,56,953.35 | 41.80 | +12.60% | |
| ₹11,565.50 | +4.22% | ₹3,07,027.69 | 87.50 | +73.75% | |
| ₹4,780.00 | +0.15% | ₹1,81,815.84 | 86.50 | +33.52% | |
| ₹2,454.00 | +3.54% | ₹1,32,592.62 | 96.10 | +149.86% | |
| ₹1,215.90 | +1.37% | ₹1,21,286.49 | 27.80 | +28.79% | |
| ₹1,385.00 | +1.09% | ₹1,15,603.22 | 41.40 | +14.90% | |
| ₹1,403.80 | -0.14% | ₹1,13,407.17 | 40.00 | -6.77% | |
| ₹2,668.30 | +3.31% | ₹1,10,212.82 | 47.00 | +17.97% | |
| ₹1,855.30 | +2.84% | ₹1,06,749.86 | 26.10 | +65.09% | |
| ₹2,025.00 | +1.40% | ₹92,601.22 | 17.50 | +2.70% | |
| ₹2,671.10 | +2.94% | ₹75,385.03 | 50.50 | +47.45% | |
| ₹5,398.50 | +1.78% | ₹64,547.17 | 28.80 | -4.76% |
An investment of ₹10,000 made 5 years ago in Orchid Pharma is now worth
₹ 21,958.00
giving a profit of
₹ 11,958.00 (119.58%)
Note: Past profits do not guarantee future returns.